Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

TELIX Aktie

 >TELIX Aktienkurs 
6.696 EUR    +1.7%    (Tradegate)
Ask: 6.698 EUR / 1500 Stück
Bid: 6.6 EUR / 1000 Stück
Tagesumsatz: 3146 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
TELIX Aktie über LYNX handeln
>TELIX Performance
1 Woche: +2,6%
1 Monat: -5,0%
3 Monate: -29,8%
6 Monate: -49,3%
1 Jahr: -56,8%
laufendes Jahr: +1,3%
>TELIX Aktie
Name:  TELIX PHARMACEUTICALS LTD
Land:  Australien
Sektor:  Gesundheit
ISIN/ Wkn:  AU000000TLX2 / A2H7JK
Symbol/ Ticker:  T3X (Frankfurt)
Kürzel:  FRA:T3X, ETR:T3X, T3X:GR
Index:  -
Webseite:  https://telixpharma.com/
Profil:  Telix Pharmaceuticals Limited is a global, commerc..
>Volltext..
Marktkapitalisierung:  2181.27 Mio. EUR
Unternehmenswert:  2361.21 Mio. EUR
Umsatz:  586.57 Mio. EUR
EBITDA:  37.46 Mio. EUR
Nettogewinn:  9.44 Mio. EUR
Gewinn je Aktie:  0.03 EUR
Schulden:  361.84 Mio. EUR
Liquide Mittel:  179.22 Mio. EUR
Operativer Cashflow:  18.1 Mio. EUR
Bargeldquote:  0.69
Umsatzwachstum:  43.72%
Gewinnwachstum:  -69.63%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  TELIX
Letzte Datenerhebung:  18.01.26
>TELIX Kennzahlen
Aktien/ Unternehmen:
Aktien: 338.78 Mio. St.
Frei handelbar: 79.16%
Leerverk. Aktien: -
Rückkaufquote: -0.04%
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 123.59%
Bewertung:
KGV: 257.9
KGV lG: 1366.14
KUV: 3.68
KBV: 6.29
PEG-Ratio: -
EV/EBITDA: 63.03
Rentabilität:
Bruttomarge: 58.05%
Gewinnmarge: 1.61%
Operative Marge: 4.51%
Managementeffizenz:
Gesamtkaprendite: 1.3%
Eigenkaprendite: 3.18%
>TELIX Peer Group

Es sind 56 Aktien bekannt.
 
16.01.26 - 20:24
 First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study (GlobeNewswire EN)
 
MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of the Prostate Avoidance Stratification Study), a Phase 3 trial to evaluate the use of Telix's commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the initial prostate cancer diagnosis setting. The dose was administered under the supervision of Dr. Brian Mazzarella at Urology Austin and supplied by RLS Radiopharmacies....
09.01.26 - 15:06
 Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX (PR Newswire)
 
NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix......
08.01.26 - 19:03
 Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman (PR Newswire)
 
Partner Reed Kathrein Urges Investors to Contact Firm Before January 9, 2026 Lead Plaintiff Deadline SAN FRANCISCO, Jan. 8, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the......
08.01.26 - 17:54
 Berger Montague: DEADLINE TOMORROW: Berger Montague Advises Telix Pharmaceuticals Ltd. (TLX) Investors to Inquire About a Securities Fraud Class Action by January 9, 2026 (Newsfile)
 
Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals......
08.01.26 - 12:03
 Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference (GlobeNewswire EN)
 
MELBOURNE, Australia and INDIANAPOLIS, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA (U.S.). ...
07.01.26 - 21:33
 Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
 
LOS ANGELES, Jan. 7, 2026 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). IF YOU SUFFERED A LOSS ON YOUR......
07.01.26 - 17:54
 Faruqi & Faruqi LLP: INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals (Newsfile)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their OptionsIf you purchased or acquire......
06.01.26 - 22:12
 Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
 
LOS ANGELES, Jan. 6, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO......
06.01.26 - 21:42
 TLX Deadline: TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm (PR Newswire)
 
NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period"), of the important January 9,......
06.01.26 - 15:48
 Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman (PR Newswire)
 
Partner Reed Kathrein Urges Investors to Contact Firm Before January 9, 2026 Lead Plaintiff Deadline SAN FRANCISCO, Jan. 6, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix Pharmaceuticals Ltd. (NASDAQ: TLX) that the......
06.01.26 - 15:01
 Telix Pharmaceuticals Ltd. Sued for Securities Law Violations - Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX (PR Newswire)
 
NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix......
06.01.26 - 14:54
 Berger Montague: Telix Pharmaceuticals Ltd. (TLX) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit (Newsfile)
 
Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals......
06.01.26 - 02:30
 Faruqi & Faruqi LLP: SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals (Newsfile)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Telix to Contact Him Directly to Discuss Their OptionsIf you purchased or acquire......
05.01.26 - 15:06
 Investors in Telix Pharmaceuticals Ltd. Should Contact The Gross Law Firm Before January 9, 2026 to Discuss Your Rights - TLX (PR Newswire)
 
NEW YORK, Jan. 5, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff......
05.01.26 - 14:39
 TELIX PHARMACEUTICALS (NASDAQ: TLX) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by January 9, 2026 (PR Newswire)
 
PHILADELPHIA, Jan. 5, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the......
04.01.26 - 14:54
 Faruqi & Faruqi LLP: SHAREHOLDER ALERT: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 (Newsfile)
 
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their OptionsIf you purchased or acquire......
03.01.26 - 15:03
 TLX 6-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures (PR Newswire)
 
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO, Jan. 3, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix......
02.01.26 - 19:18
 Berger Montague: ATTENTION TELIX PHARMACEUTICALS (TLX) SHAREHOLDERS: Securities Fraud Lawsuit Filed Against Telix Pharmaceuticals Ltd. (Newsfile)
 
Philadelphia, Pennsylvania--(Newsfile Corp. - January 2, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals......
02.01.26 - 15:03
 Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. Lawsuit - TLX (PR Newswire)
 
NEW YORK, Jan. 2, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix......
01.01.26 - 15:03
 21% TLX PLUNGE: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures (PR Newswire)
 
Partner Reed Kathrein Scrutinizing Alleged Misstatements on Prostate Cancer Drug TLX591 Progress and Third-Party Manufacturing Deficiencies (Form 483) SAN FRANCISCO, Jan. 1, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is issuing a reminder to investors in Telix......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der Leichenwäscher gibt keine Gewähr für das Paradies. - Sprichwort Afrika
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!